# FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)

> **NCT01328171** · PHASE2 · COMPLETED · sponsor: **AIO-Studien-gGmbH** · enrollment: 93 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** FOLFOXIRI + Panitumumab
- **DRUG:** FOLFOXIRI

## Key facts

- **NCT ID:** NCT01328171
- **Lead sponsor:** AIO-Studien-gGmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2017-06
- **Final completion:** 2022-01
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2023-06-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01328171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01328171, "FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01328171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*